Along the lines of glucose metabolism, sodium-glucose cotransporter-2 (SGLT2) inhibitor, another anti-diabetic drug, that could prevent glucose reabsorption in the kidney, was shown to low stroke risk in patients with diabetes and atrial fibrillation (Chang et al., 2023). Here, SLC5A2 is linked to stroke disorder.